BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 7657130)

  • 1. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis.
    Pasricha PJ; Bedi A; O'Connor K; Rashid A; Akhtar AJ; Zahurak ML; Piantadosi S; Hamilton SR; Giardiello FM
    Gastroenterology; 1995 Sep; 109(3):994-8. PubMed ID: 7657130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac.
    Keller JJ; Offerhaus GJ; Polak M; Goodman SN; Zahurak ML; Hylind LM; Hamilton SR; Giardiello FM
    Gut; 1999 Dec; 45(6):822-8. PubMed ID: 10562579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
    Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
    BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis.
    Nugent KP; Farmer KC; Spigelman AD; Williams CB; Phillips RK
    Br J Surg; 1993 Dec; 80(12):1618-9. PubMed ID: 8298943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis.
    Winde G; Schmid KW; Brandt B; Müller O; Osswald H
    Dis Colon Rectum; 1997 Oct; 40(10):1156-68; discussion 1168-9. PubMed ID: 9336110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The effects of sulindac on the pathology of colorectal remnant polyps of familial adenomatous polyposis (FAP) patients].
    Li J; Lv YM; Jin Z; Cui RL
    Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Aug; 37(4):371-3. PubMed ID: 16086054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial.
    Samadder NJ; Kuwada SK; Boucher KM; Byrne K; Kanth P; Samowitz W; Jones D; Tavtigian SV; Westover M; Berry T; Jasperson K; Pappas L; Smith L; Sample D; Burt RW; Neklason DW
    JAMA Oncol; 2018 May; 4(5):671-677. PubMed ID: 29423501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment.
    Spagnesi MT; Tonelli F; Dolara P; Caderni G; Valanzano R; Anastasi A; Bianchini F
    Gastroenterology; 1994 Feb; 106(2):362-6. PubMed ID: 8299902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors.
    Giardiello FM; Offerhaus JA; Tersmette AC; Hylind LM; Krush AJ; Brensinger JD; Booker SV; Hamilton SR
    Gut; 1996 Apr; 38(4):578-81. PubMed ID: 8707091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of a low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months.
    Winde G; Schmid KW; Schlegel W; Fischer R; Osswald H; Bünte H
    Dis Colon Rectum; 1995 Aug; 38(8):813-30. PubMed ID: 7634976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients.
    Koornstra JJ; Rijcken FE; Oldenhuis CN; Zwart N; van der Sluis T; Hollema H; deVries EG; Keller JJ; Offerhaus JA; Giardiello FM; Kleibeuker JH
    Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1608-12. PubMed ID: 16030090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
    Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
    Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rectal epithelial apoptosis does not predict response to sulindac treatment or polyp development in presymptomatic familial adenomatous polyposis patients.
    Keller JJ; Offerhaus GJ; Hylind LM; Giardiello FM
    Cancer Epidemiol Biomarkers Prev; 2002 Jul; 11(7):670-1. PubMed ID: 12101116
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis.
    Giardiello FM; Hamilton SR; Krush AJ; Piantadosi S; Hylind LM; Celano P; Booker SV; Robinson CR; Offerhaus GJ
    N Engl J Med; 1993 May; 328(18):1313-6. PubMed ID: 8385741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study.
    Cruz-Correa M; Hylind LM; Romans KE; Booker SV; Giardiello FM
    Gastroenterology; 2002 Mar; 122(3):641-5. PubMed ID: 11874996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular analysis of sulindac-resistant adenomas in familial adenomatous polyposis.
    Keller JJ; Offerhaus GJ; Drillenburg P; Caspers E; Musler A; Ristimäki A; Giardiello FM
    Clin Cancer Res; 2001 Dec; 7(12):4000-7. PubMed ID: 11751493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulindac in familial adenomatous polyposis: evaluation by nuclear morphometry.
    Fernández-López F; Conde-Freire R; Cadarso-Suárez C; García-Iglesias J; Puente-Domínguez JL; Potel-Lesquereux J
    Eur J Surg; 2001 May; 167(5):375-81. PubMed ID: 11419555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulindac causes regression of rectal polyps in familial adenomatous polyposis.
    Labayle D; Fischer D; Vielh P; Drouhin F; Pariente A; Bories C; Duhamel O; Trousset M; Attali P
    Gastroenterology; 1991 Sep; 101(3):635-9. PubMed ID: 1650315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between APC genotype, polyp distribution, and oral sulindac treatment in the colon and rectum of patients with familial adenomatous polyposis.
    Guldenschuh I; Hurlimann R; Muller A; Ammann R; Mullhaupt B; Dobbie Z; Zala GF; Flury R; Seelentag W; Roth J; Meyenberger C; Fried M; Hoppeler T; Spigelman AD; Scott RJ
    Dis Colon Rectum; 2001 Aug; 44(8):1090-7; discussion 1097-9. PubMed ID: 11535846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis.
    Stoner GD; Budd GT; Ganapathi R; DeYoung B; Kresty LA; Nitert M; Fryer B; Church JM; Provencher K; Pamukcu R; Piazza G; Hawk E; Kelloff G; Elson P; van Stolk RU
    Adv Exp Med Biol; 1999; 470():45-53. PubMed ID: 10709673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.